➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Medtronic
Merck
Mallinckrodt
Moodys
Harvard Business School

Last Updated: August 14, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TD-4208

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Clinical Trials for TD-4208

Trial ID Title Status Sponsor Phase Summary
NCT01704404 7 Days of TD−4208 in Subjects With Chronic Obstructive Pulmonary Disease Completed Theravance Biopharma R & D, Inc. Phase 2 This study will characterize the dose response of TD-4208 after 7 days of dosing in subjects with Chronic Obstructive Pulmonary Disease (COPD).
NCT02040792 A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD) Completed Theravance Biopharma R & D, Inc. Phase 2 This study evaluated the safety and efficacy of four doses of TD-4208 and a placebo product when administered once daily for 28 days using a jet nebulizer to patients with moderate to severe chronic obstructive pulmonary disease.
NCT02109172 A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD) Completed Theravance Biopharma R & D, Inc. Phase 2 This study evaluated the safety and efficacy of once and twice daily TD-4208 and placebo when administered using a jet nebulizer for 7 days in a cross-over design to patients with moderate to severe chronic obstructive pulmonary disease.
NCT02459080 Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD) Completed Theravance Biopharma R & D, Inc. Phase 3 The purpose of this study is to measure the effectiveness and safety of TD 4208, an investigational drug being developed to treat people with moderate to very severe COPD, compared to placebo, a treatment without activity.
NCT02512510 Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD) Completed Theravance Biopharma R & D, Inc. Phase 3 The purpose of this study is to measure the effectiveness and safety of TD 4208, an investigational drug being developed to treat people with moderate to very severe COPD, compared to placebo, a treatment without activity.
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for TD-4208

Condition Name

Condition Name for
Intervention Trials
Chronic Obstructive Pulmonary Disease (COPD) 5
COPD 3
Chronic Obstructive Pulmonary Disease, COPD 1
Chronic Obstructive Pulmonary Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for
Intervention Trials
Lung Diseases, Obstructive 10
Lung Diseases 10
Pulmonary Disease, Chronic Obstructive 10
Respiratory Aspiration 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for TD-4208

Trials by Country

Trials by Country for
Location Trials
United States 11
New Zealand 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for
Location Trials
South Carolina 4
Florida 2
Oregon 2
Arizona 1
Nebraska 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for TD-4208

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 3 5
Phase 2 4
Phase 1/Phase 2 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Completed 10
Active, not recruiting 2
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for TD-4208

Sponsor Name

Sponsor Name for
Sponsor Trials
Theravance Biopharma R & D, Inc. 12
Mylan Inc. 1
Theravance Biopharma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKinsey
Medtronic
McKesson
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.